Redo orthotopic heart transplantation in the current era
The Journal of Thoracic and Cardiovascular Surgery · 2023-08 · 166 (2) · 583-594.e3
DOI: 10.1016/j.jtcvs.2021.09.061 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2023-08. Verfasst von Nicholas R Hess und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiac Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pa. Hauptthemen laut MEDLINE: Ventricular Function, Left, Heart Transplantation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Medtronic.
Abstract (Originalsprache)
OBJECTIVE: This study aims to investigate the trends, outcomes, and risk factors for mortality after redo orthotopic heart transplantation. METHODS: The United Network for Organ Sharing registry was used to identify adult orthotopic heart transplantation recipients from 2000 to 2020 and stratify into primary and redo cohorts. Five-year post-transplant survival was compared between 2 propensity-matched cohorts. Multivariable modeling was performed to identify risk-adjusted predictors of redo post-transplant mortality, both conditional and nonconditional on shorter-term survival. RESULTS: A total of 40,711 recipients were analyzed, 39,657 (97.4%) primary and 1054 (2.6%) redo. Redo recipients had a lower median age and were more frequently bridged with intravenous inotropes, intra-aortic balloon pump, or extracorporeal membrane oxygenation (all P < .05). One- and 5-year survivals were lower after redo orthotopic heart transplantation (90.0% vs 83.4% and 77.6% vs 68.6%, respectively) and remained lower after comparing 2 propensity-matched cohorts. Multivariable modeling found factors such as increasing donor age and graft ischemic times, along with pretransplant mechanical ventilation and blood transfusion, to negatively affect 90-day survival. Contingent on 1-year survival, donor factors such as hypertension (hazard ratio, 1.51; 95% confidence interval, 1.15-2.00, P = .004) and left ventricular ejection fraction less than 50% (hazard ratio, 2.22, 95% confidence interval, 1.16-4.24, P = .016) negatively affected survival at 5 years. CONCLUSIONS: Although infrequently performed, redo orthotopic heart transplantation remains associated with worse post-transplant outcomes compared with primary orthotopic heart transplantation. Although several high-risk features were identified to affect post-retransplant outcomes in the acute perioperative period, donor characteristics such as hypertension and decreased ejection fraction continue to have lasting negative impacts in the longer term.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiac Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pa.
- Division of Cardiology, University of Pittsburgh Medical Center, Pittsburgh, Pa.
- Division of Cardiac Surgery, Medical University of South Carolina, Charleston, SC. Electronic address: kilica2@upmc.edu.
Förderung
- Medtronic
Zitieren
APA
Hess, N. R., Hickey, G. W., Sultan, I., & Kilic, A. (2023). Redo orthotopic heart transplantation in the current era. The Journal of Thoracic and Cardiovascular Surgery, 166(2), 583-594.e3. https://doi.org/10.1016/j.jtcvs.2021.09.061
Vancouver
Hess NR, Hickey GW, Sultan I, Kilic A. Redo orthotopic heart transplantation in the current era. The Journal of Thoracic and Cardiovascular Surgery. 2023;166(2):583-594.e3. doi:10.1016/j.jtcvs.2021.09.061
BibTeX
@article{Hess2023,
author = {Hess, Nicholas R and Hickey, Gavin W and Sultan, Ibrahim and Kilic, Arman},
title = {Redo orthotopic heart transplantation in the current era},
journal = {The Journal of Thoracic and Cardiovascular Surgery},
year = {2023},
volume = {166},
number = {2},
pages = {583--594.e3},
doi = {10.1016/j.jtcvs.2021.09.061}
}
EUVIMED